Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with In silico target peptide selection

Journal of Pharmaceutical Sciences

Volumn 100, Issue 1, 2011, Pages 341-352

  Kawakami, Hirotaka ^a   Ohtsuki, Sumio ^a   Kamiie, Junichi ^b   Suzuki, Takashi ^c   Abe, Takaaki ^c   Terasaki, Tetsuya ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b AZABU UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP enzymes; Cytochrome P450; Hepatic metabolism; LC MS MS; Mass spectrometry; Metabolism; Microsomes; Proteomics; Quantification

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3C8; CYTOCHROME P450 3C9; PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 78650054715     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22255     Document Type: Article

References (28)

1. Lewis DF. 2004. 57 varieties: The human cytochromes P450. Pharmacogenomics 5: 305-318.
2. Guengerich FP. 2003. Cytochromes P450, drugs, and diseases. Mol Interv 3: 194-204.
3. Aebersold R, Mann M. 2003. Mass spectrometry-based proteomics. Nature 422: 198-207.
4. Patterson SD, Aebersold RH. 2003. Proteomics: The first decade and beyond. Nat Genet 33: 311-323.
5. Domon B, Aebersold R. 2006. Mass spectrometry and protein analysis. Science 312: 212-217.
6. Picotti P, Bodenmiller B, Mueller LN, Domon B, Aebersold R. 2009. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 138: 795-806.
7. Wang MZ, Wu JQ, Dennison JB, Bridges AS, Hall SD, Kornbluth S, Tidwell RR, Smith PC, Voyksner RD, Paine MF, Hall JE. 2008. A gel-free MS-based quantitative proteomic approach accurately measures cytochrome P450 protein concentrations in human liver microsomes. Proteomics 8: 4186-4196.
8. Langenfeld E, Zanger UM, Jung K, Meyer HE, Marcus K. 2009. Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver. Proteomics 9: 2313-2323.
9. Seibert C, Davidson BR, Fuller BJ, Patterson LH, Griffiths WJ, Wang Y. 2009. Multiple-approaches to the identification and quantification of cytochromes P450 in human liver tissue by mass spectrometry. J Proteome Res 8: 1672-1681.
10. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, Terasaki T. 2008. Quantitative atlas of membrane transporter proteins: Development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25: 1469-1483.
11. Shilov IV, Seymour SL, Patel AA, Loboda A, Tang WH, Keating SP, Hunter CL, Nuwaysir LM, Schaeffer DA. 2007. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics 6: 1638-1655.
12. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423.
13. Andersen JS, Wilkinson CJ, Mayor T, Mortensen P, Nigg EA, Mann M. 2003. Proteomic characterization of the human centrosome by protein correlation profiling. Nature 426: 570-574.
14. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. 2007. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 6: 2212-2229.
15. Kuster B, Schirle M, Mallick P, Aebersold R. 2005. Scoring proteomes with proteotypic peptide probes. Nat Rev Mol Cell Biol 6: 577-583.
16. Redlich G, Zanger UM, Riedmaier S, Bache N, Giessing AB, Eisenacher M, Stephan C, Meyer HE, Jensen ON, Marcus K. 2008. Distinction between human cytochrome P450 (CYP) isoforms and identification of new phosphorylation sites by mass spectrometry. J Proteome Res 7: 4678-4688.
17. Inoue S, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT, Rostami-Hodjegan A. 2006. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences. Xenobiotica 36: 499-513.
18. Mori K, Blackshear PE, Lobenhofer EK, Parker JS, Orzech DP, Roycroft JH, Walker KL, Johnson KA, Marsh TA, Irwin RD, Boorman GA. 2007. Hepatic transcript levels for genes coding for enzymes associated with xenobiotic metabolism are altered with age. Toxicol Pathol 35: 242-251.
19. Fradette C, Batonga J, Teng S, Piquette-Miller M, du Souich P. 2007. Animal models of acute moderate hypoxia are associated with a down-regulation of CYP1A1, 1A2, 2B4, 2C5, and 2C16 and up-regulation of CYP3A6 and P-glycoprotein in liver. Drug Metab Dispos 35: 765-771.
20. Hunt CM, Westerkam WR, Stave GM. 1992. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44: 275-283.
21. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger UM. 2003. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38: 978-988.
22. Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, Larsson H, Bodin KG, Allqvist A, Jande M, Kim JW, Aklillu E, Gustafsson LL, Bertilsson L. 2008. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: Relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 18: 201-208.
23. Somlo G, Doroshow JH, Synold T, Longmate J, Reardon D, Chow W, Forman SJ, Leong LA, Margolin KA, Morgan RJ Jr, Raschko JW, Shibata SI, Tetef ML, Yen Y, Kogut N, Schriber J, Alvarnas J. 2001. High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: Toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Br J Cancer 84: 1591-1598.
24. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M. 1994. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54: 386-392.
25. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Vigano L, Locatelli A, Verweij J, Sparreboom A, McLeod HL. 2005. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11: 8097-8104.
26. Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y, Tanaka M, Inoue M, Yokoi T. 2005. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 45: 674-682.
27. Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW. 2007. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 7: 362-365.
28. Gillam EM, Guo Z, Ueng YF, Yamazaki H, Cock I, Reilly PE, Hooper WD, Guengerich FP. 1995. Expression of cytochrome P450 3A5 in Escherichia coli: Effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 317: 374-384.